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Activated complement protein C5a does 
not affect brain‑derived endothelial cell 
viability and zonula occludens‑1 levels 
following oxygen‑glucose deprivation
Aren Khoyetsyan, Rachid Kacimi1,2, Gohar Tsakanova, Anna Boyajyan, 
Arsen Arakelyan, Midori A Yenari1,2
Abstract:
BACKGROUND AND PURPOSE: Ischemic brain injury induces both functional and structural disarray 
affecting the blood–brain barrier (BBB) which in return aggravates stroke outcomes. Complement 
system and its bioactive proteins are important molecular responders to ischemia. C5a protein along 
with its receptor C5a receptor 1 is a key component of this system with potent pro-inflammatory and 
chemoattractant properties. The purpose of this study is to investigate the role of C5a protein and its 
receptor which are believed to participate in the inflammatory response that follows ischemic insult.
MATERIALS AND METHODS: To mimic an ischemic in vivo event in which C5a may contact brain 
endothelial cells after injury, we studied oxygen‑glucose deprivation (OGD) followed by reperfusion in 
brain microvascular endothelial cells (b.End. 3) by only added C5a at the time of reperfusion. Cell death 
and viability were estimated by trypan blue and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assays, respectively. Tight junction protein zonula occluden (ZO‑1) levels were analyzed 
by Western blot analysis, and nitric oxide (NO) was assessed using the Griess reagent.
RESULTS: Brain‑derived endothelial cell was susceptible to OGD‑induced injury in a duration‑dependent 
manner as was the presence of ZO‑1 protein. However, the addition of C5a protein had no notable effects 
even when used at high concentrations up to 100 nM. While OGD led to reduction in ZO‑1 protein levels, 
no change was seen following the addition of C5a. Finally, OGD led unexpectedly to small decreases in 
NO generation, but this was again unaltered by C5a.
CONCLUSIONS: Our study suggests that complement system protein C5a may not have a direct 
role in the disruption of BBB, following brain ischemia. This is in contrary with previous literature that 
suggests a possible role of this protein in the inflammatory response to ischemia.
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Introduction
Despite remarkable advancements in elucidating the hallmarks of ischemic 
brain injury, stroke remains a leading cause 
of morbidity and mortality worldwide due 
to the lack of effective therapies.[1] Among the 
various pathobiological processes associated 
with ischemia, there is emerging evidence that 
highlights the possible role of neurovascular 
unit in worsening the damage following 
stroke. This unit includes endothelial cells 
which are a central player in controlling 
blood–brain barrier (BBB) permeability 
and maintenance.[2,3] The integrity of BBB is 
susceptible to a wide range of processes that 
are also believed to exacerbate stroke severity 
and outcomes.[4-7] Systemic inflammation is an 
important example of such processes and is 
in part controlled by the complement system.
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As a host defense mechanism that functions to eliminate 
foreign pathogens and opsonize necrotic cells, the 
complement system is considered a vital component 
of our innate immunity. It consists of more than sixty 
plasma and membrane bound proteins, receptors, and 
regulators that collectively work together to confer 
immunity. Currently, four biochemical pathways have 
been discovered that activate the complement system: 
classical complement pathway, alternative complement 
pathway, lectin pathway, and recently discovered 
extrinsic protease pathway.[8-14] First three pathways 
are initiated by the binding of complement factor C1q 
to antigen–antibody complexes, foreign surface, or by 
the binding of mannan‑binding lectin to specifically 
arranged mannose residues. This eventually leads to the 
formation of C3 and C5 convertase enzymes, which cleave 
their respective inactive complement factors, C3 and 
C5, into their active fragments: C3a, C3b and C5a, C5b, 
respectively. In addition, the fourth pathway is initiated 
through the direct cleavage of C5 by a series of proteolytic 
enzymes such as kallikrein and thrombin, resulting in the 
release of bioactive C5a fragment.[14,15]
C5a is a fluid‑phase inflammatory mediator that consists 
of 74 amino acids. It acts as an anaphylatoxin with potent 
pro‑inflammatory and chemoattractant properties. C5a 
both recruits immune cells to the site of injury through 
chemotaxis and activates them to induce an inflammatory 
response. It exerts its major effects through binding to the 
membrane‑bound G‑protein coupled first‑identified C5a 
receptor 1 (C5AR1).[16] Thus, depending on the pathologic 
condition and cell type, C5a signaling can lead to various 
outcomes, including phagocytosis.
Unlike peripheral tissues, the central nervous 
system (CNS) is immunologically separated from 
systemic complement system due to the restriction 
of cell penetration by the BBB.[17] However, CNS can 
internally express all complement factors, including C5, 
and cell-derived proteases necessary to generate C5a.[18] 
Furthermore, primary and secondary cellular receptors 
including C5a, C5AR1, and C5a-like receptor 2 have been 
reported to be on all CNS cells suggesting a functional 
role for C5a in the brain.[19]
On the other hand, pathological complement system 
activation and the generation of C5a could also have 
damaging effects exacerbating CNS diseases.[19] For 
example, following ischemia, the complement system 
activates a set of bioactive molecules, including 
C5a.[20] C5a generation and the activation of C5AR1 
are gaining increasing attention as potential players 
in the neuroinflammatory response, following an 
ischemic insult.[20-24] Thus, its regulation and control of 
this system are salient as a potential target for future 
stroke therapies. However, all prior investigations have 
been limited to investigating only one strategy: C5AR1 
blocking.[23-25] The goal of the present study is to further 
elucidate the direct role of C5a in an in vitro BBB model 
of ischemia-reperfusion injury. To this end, we looked 
at oxygen-glucose deprivation (OGD) followed by 
reperfusion in murine brain microvascular endothelial 
cells (b.End. 3) subjected to OGD with and without C5a 
protein.
Materials and Methods
Chemicals and reagents
Reagents of analytical grade and MilliQ water were 
used. Dulbecco’s Modified Eagle Medium (DMEM) 
and the immortalized b.End. 3 were purchased from 
American Type Culture Collection (Manassas, VA, 
USA). Fetal bovine serum (FBS) was purchased from 
Hyclone Laboratories (Logan, UT, USA). Trypsin/
ethylenediaminetetraacetic acid solution, polyclonal rabbit 
anti-zonula occluden (ZO-1) antibody, and other cell culture 
reagents were purchased from Invitrogen Inc. (Camarillo, 
CA, USA) and the UCSF Cell Culture Facility (UCSF, 
San Francisco, CA, USA). Mouse recombinant C5a was 
purchased from ProSpec (East Brunswick, NJ, USA). 
C5a was dissolved in sterile 18 M-cm H2O (at stock 
concentration 100 µg/ml), and aliquots were stored for 
later use at − 20°C. C5a reconstitution was performed 
according to the manufacturer recommendations. 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and Greiss reagent were purchased 
from Sigma (St. Louis, MO, USA). Balanced salt solution 
containing 116 mM NaCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 
5.4 mM KCl, 1 mM NaH2PO4, 14.7 mM NaHCO3, 10 
mM N-(2-hydroxyethyl) piperazine-N-ethane sulfonic 
acid (HEPES), and 10 mg/l phenol red at pH 7.4 (BSS0, 
glucose free) and 5.5 mM glucose (BSS5.5, with glucose) 
were used in the experiments with several OGD conditions. 
Culture flasks and plates were from BD Biosciences 
Labware. Protease inhibitor cocktail complete mini was 
obtained from Roche diagnostics.
Cell culture, treatment, and ischemia‑like injury 
model
The immortalized mouse b.END.3 was used in this study. 
Cells were cultured in adjusted DMEM supplemented 
with 4.5 g/ml glucose, 10% FBS defined, and antibiotics.
All cells were maintained at 37°C in a humidified 
atmosphere of 5% CO2 and 95% air. All experiments were 
performed in approximately 80% confluent monolayers 
with a cell density of nearly 0.5 × 106, verified before 
use. Cells were treated by recombinant mouse C5a 
protein (10–100 nM). Cultures were washed three times 
in C5a containing media and then were returned to the 
incubator. Control cultures were washed only in plating 
media.
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For ischemia-like injury model, OGD followed by 
reperfusion was carried out. Cell cultures were deprived 
of glucose and oxygen by transferring into an anaerobic 
chamber (O2 <0.2%, COY Lab Products, MI, USA) and 
changing the culture medium to oxygen-, glucose-free 
balanced salt solution (BSS0) for 2, 4, and 6 h. After 
incubation at OGD conditions, the cultures were 
returned to the normoxia by adding 5.5 mM glucose to 
the culture medium (reperfusion step) and transferring 
into the incubator. Control cultures were washed 
only in BSS5.5 but were maintained in the normoxic 
environment. Recombinant mouse C5a protein was 
added on set up before the reperfusion step with a tested 
beforehand intermediate concentration not causing 
toxicity to primary cells. The total observation period 
for OGD experiments with following reperfusion was 
24 h. The cultures that were not exposed to OGD were 
considered to be kept at normoxia (controls).
Cell death and viability assessment
Cell death and viability were assessed by trypan blue 
staining and MTT functional assay, respectively. Five 
random high power fields were selected, and total cell 
counts and trypan blue positive (dead) cell counts were 
made.
The MTT assay measures mitochondrial respiration, an 
index of cell viability. At the indicated times, appreciate 
volumes of 5 mg/ml MTT solution in PBS were added to 
each well for 4 h at 37°C. After removal of the medium, 
dimethyl sulfoxide was added to each well to dissolve 
the formazan crystals. The absorbance at 570 nm was 
determined using a microplate reader. All experiments 
were performed in triplicates. The percentage of 
absorbance in each sample versus the control was 
calculated to assess the cell viability.
Nitric oxide assay
Nitric oxide (NO) levels in culture media, BSS0 and 
BSS5.5, were estimated for 2 and 4 h of OGD with 5 
and 24 h of reperfusion period using Greiss reagent (1% 
sulfanilamide and 0.1% N-1-naphthy-ethylenediamine 
dihydrochloride in 5% phosphoric acid) with nitrite as 
the standard according to protocol recommendation.[26,27] 
The absorbance at 570 nm was then determined using a 
microplate reader and a standard curve was generated 
using NaNO2. Total cellular protein was measured by the 
bicinchoninic acid (BCA)-based method (Pierce, USA).
Western blot analysis of zonula occludens‑1 
protein expression
Cells were harvested by scraping and washing in ice-cold 
PBS and lysed with ice-cold cell lysis buffers (50 mM 
Tris, pH 8.0; 150 mM NaCl, 1% triton X-100, and protease 
inhibitor cocktail complete mini), followed by sonication 
and centrifugation for 5 min. BCA protein assay (Pierce, 
Rockford, IL, USA) was used for the determination 
of protein concentration in the supernatant. The 
supernatant was used for further steps. Equal amounts 
of protein were loaded on 7.5% polyacrylamide 
gels, and SDS-PAGE (Bio-Rad Laboratories, Inc., 
USA) was performed according the previously 
described protocol.[27-29] After separation, proteins were 
electrophoretically transferred to polyvinyl difluoride 
membranes (Immuno-Blot PVDF membrane, Bio-Rad, 
USA) and blocked with 4% fat-free milk in PBS (pH 7.4) 
overnight. The membranes then were incubated with a 
1:1000 dilution of primary rabbit polyclonal anti-mouse 
ZO-1 antibody for 1 h at room temperature and then 
incubated with a 1:10,000 dilution of secondary antibody 
conjugated with horseradish peroxidase for 1 h at 
room temperature. After the blots were incubated with 
secondary antibodies, bands were visualized using the 
enhanced Amersham ECL Western Blotting Detection 
Kit (GE Healthcare Life Sciences, US). B-actin was used as 
a housekeeping control. All experiments were performed 
in triplicates and analyzed by an investigator blinded to 
experimental conditions.
Data analysis
Statistical analysis was performed using one-way 
ANOVA (GraphPad 5 Software, Graphpad Software 
Inc., La Jolla, CA, USA). All data were expressed as 
mean ± standard deviation. Significance was assumed 
for P < 0.05. All experiments were carried out in a 
randomized fashion, with each experiment performed 
three times from three different culture sets. Investigators 
analyzing the data did so in a blinded fashion.
Results
To investigate the direct role of C5a in an ischemia-like 
injury model of BBB, we first estimated the influence 
of OGD duration on b.End. 3 cells. This allowed us to 
determine the duration of OGD necessary to cause <40% 
and >80% cell death. Cell death was estimated by 
trypan blue staining and viability was measured by 
MTT assay. Results showed that OGD for 2 h did not 
affect cell death or viability. However, there was ~40% 
and ~80% cell death [Figure 1a] and ~20% and 5% cell 
viability [Figure 1b] when OGD was continued for 4 and 
6 h, respectively, and assessed 24 h later.
Before evaluating any effect of C5a on in vitro model 
of BBB, we examined cytotoxicity of C5a on b.End. 
3 cells under normoxia conditions and found that C5a, 
even at concentrations up to 100 nM, did not affect cell 
viability (data are not presented).
To model a potential in vivo scenario where C5a 
may contact brain endothelial cells during stroke, 
we tested C5a effect on cell viability with dosage 
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range of 10–100 nM by adding it only at the onset of 
reperfusion. Interestingly, the addition of C5a did not 
affect cell death [Figure 2]. In particular, there were no 
significant differences (P > 0.05) in the mean values of cell 
death (trypan blue) or cell viability (optical density, MTT 
assay) after OGD exposure of 4 h with (32.63 ± 1.96 and 
0.25 ± 0.026) and without (33.35 ± 3.59 and 0.22 ± 0.028) 
C5a added at the time of reperfusion (return of cultures 
to normoxia with the addition of 5.5 mM glucose to the 
culture media).
NO levels were estimated using the Griess reagent. 
b.End. 3 subjected to 4 h of OGD was somewhat lower 
than baseline levels although this did not reach statistical 
significance [Figure 3]. The addition of C5a protein at 
the time of reperfusion did not affect NO generation 
compared to OGD alone.
Western blots of ZO-1 protein were used to estimate 
BBB integrity. ZO-1 is a major tight junction (TJ) protein, 
and TJs are thought to form the basis of the BBB by 
forming a scaffold between the transmembrane proteins 
and the actin cytoskeleton.[30] Four hours OGD led to 
marked reduction in ZO-1 levels, whereas 2 h OGD did 
not [Figure 4a]. This was the rationale behind using 2 
h OGD to test our hypothesis that the addition of C5a 
might reduce ZO-1 levels. However, C5a addition failed 
to show any impact on ZO-1 levels [Figure 4b and c].
Discussion
BBB consists of a network of cerebral endothelial cells 
and associated TJs. Those junctions are formed by 
transmembrane molecules (claudin, occludin, and 
junctional adhesion molecules) that form structures with 
several actin cytoskeleton and cytoplasmic proteins, 
ZO-1, ZO-2, and ZO-3.[4,31] As was shown in previous 
research,[32] brain microvascular endothelial cell line, 
b.End. 3, demonstrates similar functional and structural 
characteristics of BBB. Those include formation of 
functional barriers, expression of the TJ proteins including 
ZO-1 as well as junctional adhesion molecules.[32] It has 
been shown that, like primary endothelial cells, b.End. 
3 cells express C5AR1 on their membranes.[33]
The role of the complement system and its various 
components in ischemic brain injury has been the 
subject of much debate. Immunohistochemical analysis 
of human brains identified the presence of multiple 
components of the complement system in ischemic brain 
including the classic pathway products (C1q, C3, C4d) 
and other components such as MASP-2 of lectin pathway, 
factor B of alternative pathway, and C9.[34] Furthermore, 
the activation of complement alternative pathway, as 
well as the protective effect of factor B deficiency and 
CR2-fH treatment in pathogenesis of murine ischemic 
stroke, was demonstrated.[35] A In addition, elevated 
levels of C3a and C5a anaphylatoxins were observed 
in blood samples from human patients with ischemic 
stroke.[36] This was further proven in an in vitro study that 
looked at various types of ischemic insults in different 
neuronal cells and showed that hypothermia-induced 
neuroprotection is enhanced by blocking C5AR1.[22] Two 
other studies with C5 deficient mice subjected to middle 
cerebral artery occlusion (MCAO) revealed that lack of 
C5 led to protective effects from ischemic injury, reduced 
lesion size, and improved neurological scores.[21,37] 
Similar results were obtained in the experiments with 
C5AR1 (−/−) mice subjected to MCAO.[25] However, 
it was also shown that those beneficial effects were 
concentration- and time-dependent.[24,37] On the other 
hand, Mocco et al. reported that C5 deficiency is not 
protective after focal cerebral ischemia.[36] All these 
studies implicated significance of blocking C5AR1 in 
terms of neuroprotection.
Figure 1: Duration‑‑dependent endothelial cell death due to oxygen‑glucose 
deprivation. Cultures of murine brain‑derived endothelial cells (b.End. 3) were 
exposed to varying durations of oxygen‑glucose deprivation followed by 24 h 
reperfusion. Cell death was estimated by trypan blue (a), whereas cell viability 
was estimated by the 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide 
assay (b). oxygen‑glucose deprivation durations of 4 and 6 h led to dose‑dependent 
cell death (~40% after 4 h, ~90% after 6 h) and cell viability (~20% after 4 h, 5% after 
6 h), whereas 2 h oxygen‑glucose deprivation had little effect on either. *P < 0.01 
versus controls. OGD: Oxygen‑glucose deprivation, Con: Controls
ba
Figure 2: C5a does not affect cell death in endothelial cells after oxygen‑glucose 
deprivation. b.End. 3 cells were exposed to 4 h oxygen‑glucose deprivation with 
and without added C5a. Cell death was assessed 24 h later by trypan blue staining 
and compared to uninjured controls. C5a concentrations of 10–100 nM (added 
C5a denoted in the X‑axis labels) failed to affect the extent of oxygen‑glucose 
deprivation‑induced cell death. OGD: Oxygen‑glucose deprivation, Con: Controls
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Recently, Jacob et al. using serum from lupus mouse 
models as a source of C5a and b.End. 3 cells demonstrated 
that C5a/C5AR1 signaling alters BBB integrity in an 
NF-κB-dependent manner.[33] Using treatment with a 
C5AR1 antagonist and silencing the C5AR1 gene with 
siRNA, it has been shown that C5aR is responsible for 
vascular endothelial cell injury in cultured mouse dermal 
microvascular endothelial cells.[32] This controversy and 
lack of studies on C5a direct role in BBB disruption 
following ischemia necessitates further investigation 
and here where the root of our paper lies.
Interestingly, our study reveals no effect of C5a protein, 
even when used in high doses, on b.End. 3 cells viability 
and ZO-1 protein levels in ischemia-like model. One 
possible explanation for this discrepancy with previous 
research may be that C5aR has multiple ligands capable 
initiating downstream signaling cascades. It is known that 
C5aR also binds to C3a and ribosomal protein S19, but 
with lower binding affinity compared to C5a.[38,39] It also 
seems that C5 and C5a target neurons during ischemia/
reperfusion rather than directly affecting the BBB. An 
in vitro study of OGD demonstrated the possibility of 
the proteolytic cleavage of C5 protein generated by 
neurons, leading to increased apoptotic cell death (in a 
C5a-dependent manner) and upregulation in C5a/C5AR1 
signaling.[22] Thus, our inability to detect any effect of 
added C5a might be explained in part by the lack of critical 
co‑factors that have yet to be identified. In addition, there 
are minor issues in the experimental design that might 
limit the ability of detect C5a effect on BBB cells. First, there 
are no actual data on the C5a levels in the brains during 
ischemia/reperfusion, which forced us to use a wide 
concentration range to test the effects of the protein on the 
cell viability or BBB integrity in a model of ischemia-like 
injury. Next, it is known that pH is changed in the brain 
during ischemia due to accumulation of lactate and 
pyruvate. However, pH drop is not implemented in the 
current model of BBB injury, and protocol modifications 
are needed in future to account for these changes. 
However, the ODG model is considered to be adequate 
to study the BBB changes and is widely used in research.
Conclusion
Overall, we conclude that C5a alone has no direct 
effects on endothelial cell viability or BBB integrity in 
Figure 3: Nitric oxide generation in the media of cell cultures subjected to 
oxygen‑glucose deprivation. b.End. 3 cells were exposed to 4 h oxygen‑glucose 
deprivation followed by 24 h reperfusion. Estimates of nitric oxide 
accumulation (nitrate) from culture media were made using the Griess reagent. 
Nonsignificant decreases in nitric oxide accumulation were detected in the media of 
oxygen‑glucose deprivation exposed cultures (4 h) compared to uninjured controls, 
but this was not affected by the addition of 100 nM C5a (4 h + C5a).  
OGD: Oxygen‑glucose deprivation, NO: Nitric oxide, Con: Controls
Figure 4: C5a does not alter zonula occludens‑1 levels in endothelial cells exposed 
to oxygen‑glucose deprivation. Representative Western blots of zonula occludens‑1 
protein are shown. b.End. 3 cells exposed to 2 h oxygen‑glucose deprivation failed 
to show any changes in zonula occludens‑1 protein, whereas 4 h oxygen‑glucose 
deprivation led to marked decreases (a). Blot shows three replicates of each 
condition plus a maker lane (center). A Western blot of actin protein is shown 
as a housekeeping control. Endothelial cell cultures were then exposed to 2 h 
oxygen‑glucose deprivation , and C5a was added to some oxygen‑glucose 
deprivation exposed cultures at a concentration of 100 nM (C5a). A representative 
Western blot shows that the addition of C5a failed to change zonula occludens‑1 
expression compared to uninjured controls (b). Quantification of Western blots from 
3 samples collected from 3 separate experiments (9 observations total) is shown in 
the graph (c). Relative optical densities from the blots are shown normalized to the 
OD of the actin proteins. OGD: Oxygen‑glucose deprivation, ZO: Zonula occludens, 
ODs: Optical densities, Con: Controls
c
b
a
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an ischemic-like environment. However, further studies 
are necessary to shed more light on this controversial 
question. The application of ischemia exposed sera to cells 
in the presence and absence of C5a blockade or studying 
models that include other BBB elements such as astrocytes 
could be the subject of future investigation.
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